An excerpt of medical management of polycystic liver disease： A position statement from the European Reference Network on Hepatological Diseases （2026 edition）
- VernacularTitle:《2026年欧洲肝病参考网络立场声明： 多囊肝病的医疗管理》摘译
- Author:
Wenting WU
1
;
Yueyong ZHU
1
Author Information
- Publication Type:Journal Article
- Keywords: Polycystic Liver Disease; Somatostatin; Europe; Practice Guideline
- From: Journal of Clinical Hepatology 2026;42(2):296-300
- CountryChina
- Language:Chinese
- Abstract: In January 2026， the European Reference Network on Hepatological Diseases released a position statement on polycystic liver disease （PLD）. Compared with existing diagnosis and treatment recommendations， this statement provides the latest practical guidance on somatostatin analogues as the sole available pharmacological intervention for severe PLD， including clear criteria for eligibility， the criteria for initiation and discontinuation of treatment， and the gaps requiring further research. This statement also defines the criteria for patient selection， treatment goals， and monitoring strategies， and these updates fully reflect the latest clinical evidence and practical needs in the management of PLD. This article gives an excerpt of the key practical recommendations from the statement.
